Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12790145 | 0.86 | LMNA (0.53) | LMNAALDH1A1SMN1; SMN2MAPK1CYP11B1 | |
| SCHEMBL12790148 | 0.86 | LMNA (0.53) | LMNAALDH1A1SMN1; SMN2MAPK1CYP11B1 | |
| SCHEMBL11433164 | 0.79 | ALDH1A1 (0.57) | LMNAALDH1A1SMN1; SMN2MAPK1CYP11B1 | |
| SCHEMBL11393201 | 0.78 | HDAC1 (0.58) | LMNAALDH1A1SMN1; SMN2MAPK1CYP11B1 | |
| SCHEMBL11388939 | 0.77 | SMN1; SMN2 (0.56) | LMNAALDH1A1SMN1; SMN2MAPK1CYP11B1 | |
| SCHEMBL12420839 | 0.76 | ALDH1A1 (0.54) | LMNAALDH1A1SMN1; SMN2MAPK1CYP11B1 | |
| SCHEMBL13940677 | 0.75 | ALDH1A1 (0.53) | LMNAALDH1A1SMN1; SMN2MAPK1CYP11B1 | |
| SCHEMBL25625991 | 0.75 | ALDH1A1 (0.56) | LMNAALDH1A1SMN1; SMN2ACKR3OGA | |
| SCHEMBL359069 | 0.74 | ACHE (0.79) | ALDH1A1ACHE | |
| SCHEMBL358435 | 0.74 | ACHE (0.79) | ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | LMNA 968/4885ALDH1A1 3556/4885SMN1; SMN2 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.